Seven months afterwards Roche Diabetes Care announced it would blockage selling its Accu-Chek mark insulin pumps in the U.S., the company is now handing off its left pump customers to Medtronic Diabetes.

Starting in Sept, any existing Roche pump customers who wish to continue using their Accu-Chek Smell or Combo systems volition start automatically receiving their supplies straight from Medtronic, unless they cop out of that service by the end of August.

We'Re told this Acc-Chek support contract runs through with February. 2021, which is the clearest ratify thus far that Roche Diabetes Care has no interest in bringing its insulin heart products back out to the American market after it stopped up selling them here at the start of 2017.

A letter dated Aug. 3 that went out to Roche pump customers explains that these PWDs (people with diabetes) "have the right to the product of your choice" and includes a 1-800 issue and email address for customers to cop out by August. 30 if they will.

Roche and Medtronic some tell us this is merely a way to guarantee continued support for Accu-Chek pump customers until their products go off warranty; spokespeople for both companies declined to say how many people are compact.

What does this mean? To atomic number 4 sort out, this does not ignoble that former Roche customers are existence forced to switch to Medtronic pumps. They will simply be receiving Accu-Chek supplies from Medtronic if they preceptor't opt out, meaningful they leave become partially of that party's database of customers. Those who cop out are welcome to find a different third-political party supplier to amaze their necessary ticker supplies (for example, Total Diabetes Supply online).

Is the idea to 'onboard' these customers to Medtronic pumps over prison term? Non officially, we're told. Medtronic tells US they won't be offering any special upgrades or trade-in offers to Accu-Chek pumpers, aside from what they already offer to novel customers. But the reality is that PWDs who remain connected Accu-Chek pumps will credible be pushed by sales reps to trade to Medtronic devices eventually.

Is this a monumental market perturbation? Not really. It's neither surprising nor unexpected that a company would phase out support of a product they no thirster deal. It's simply good business organization past Roche to give off these customers to a leading insulin heart company, whether we patients like it or not.

Only this move does confirm that Roche has no plans to atomic number 75-come in the U.S. pump market — something they were waffling just about when they made their initial January announcement.

It's right Sir Thomas More trial impression that the diabetes device market is highly volatile, and that it's hard to make it as an insulin ticker vendor in particular. The penning's been on the wall for years — after the Deltec Cozmo and Asante Snap couldn't survive — and with the recent financial struggles of Tandem Diabetes Caution, and JnJ Diabetes now evaluating the hereafter of its Animas/OneTouch pumps.

Medtronic has e'er been the elephant in the room, dominating more and more with "pet" insurance contracts and its large army of sales reps who flood doctors' offices in ways other pump companies clean tooshie't. Now, this customer hand-off from Roche just gives MedT much brawniness.

Roche hasn't fared well, in this many still comment "Roche makes a ticker?!" and it certainly hasn't brought any new innovative pump models to market in many years now; it's almost get over a antic to wonder when the company power ever launch the Solo patch pump it acquired from Medingo in 2010, surgery if America might ever see the Accu-Chek Insight pump that's sold-out in Europe here in the U.S.

This latest move by Roche is surely a strategic tone to cut off its losses and stress on more remunerative opportunities:

  • Next-Gen Meter Collaboration: In February 2017, Roche and Medtronic communicatory an accord to develop a next-gen BG meter that will weave Accu-Chek glucose monitoring technology into a future Medtronic pump organization.
  • D-Data Sharing: Roche acquired the mySugr app startup and its one million users in proto July, with plans to use that every bit a bag to develop an uncastrated spick-and-span digital weapons platform for diabetes data. (The two companies had already partnered using the Accu-Chek beat and strips). And in late July, Roche communicative a quislingism agreement with Accenture to develop that platform copulative PWDs, healthcare providers and others.
  • Closed Loop Smarts: Roche was once partnered with Dexcom on closed loop development, only that agreement fizzled and Roche began doing inner R&D along creating its own CGM, which was shown off as recently equally last yr… Now, in that respect's clearly another shift as Roche recently announced it has teamed finished with closed loop inauguration TypeZero Technologies and Senseonics, which make a 90-daylight implantable CGM that is presently before the Food and Drug Administration. The three will work at a closed-loop system system using the Accu-Chek Insight heart available overseas.
  • Patch pump? Who knows, very? The company still has the Solo patch heart in its portfolio, though we'rhenium not convinced we wish ever see it come to commercialize. TBD on it.

Share on Pinterest

Yep, anyone who thought Roche was jockeying to leave the diabetes device market altogether was wrong. The opposite is lawful: though Roche clearly has had a number of missteps over the eld, it's shaping up to personify an interesting run by Roche as we prompt into next-gen applied science with automation. The possibilities are intriguing.

With an eye to the future, Roche Crataegus oxycantha at long last be pinpointing what the diabetes market needs and evolving right with the multiplication. All the same only time testament evidence, of course.